Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urelumab + Nivolumab in Advanced Solid Tumors and B-cell NHL
NCT02253992Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2014
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of urelumab in solid tumor (advanced stage), B-cell non-Hodgkin lymphoma, sponsored by Bristol Myers Squibb. Started Sep 2014; status: terminated.
02
Drugs
urelumab
03
Conditions
solid tumor (advanced stage)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02253992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253992.